Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC
Clinical trial NCT05534113 · UNKNOWN
Trial details
- NCT number
- NCT05534113
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2025-06-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.